Menu
Pipeline & Clinical Activities
Our Pipeline
First-in-class ADCs and bispecifics against oncofetal CS
We have an extensive pre-clinical data package on the efficacy and safety of Vartumabs for cancer treatment which includes:
- Intravenous injection of Vartumabs into different rodent models results in tumor localization with little to no accumulation in healthy tissues.
- ADC formulations of Vartumabs using different drug payloads show curative effects in xenograft, allograft and patient-derived mice models of various cancers.
- Repeated high dose IV injections show no weight loss or change in blood panels of healthy and various cancer mice models.
- Anti-CD3 fusions have a similar efficacy and safety profile in mouse models, with a complete stop of tumor growth or full regression.
Response of lymphoma and colorectal cancer mice models to treatment with 3 doses of Vartumabs-ADC showing tumor regression and no change in body weight
Clinical Activities
Our first clinical study started in November 2024, and comprises a nuclear imaging basket trial with the goal of determining pharmacokinetics and biodistribution of Vartumabs in patients with solid tumors.
Our Pipeline: Pushing forward a first-in-class approach
We have obtained solid evidence of the potential efficacy and safety of Vartumabs as a cancer targeting platform. Intravenous injection of Vartumabs into animal models demonstrates high tumor specificity with no apparent off target effects. This indicative safety is supported by repeat high dose IV injections of antibody drug conjugates showing no weight loss, change in blood panels or other adverse effects in several cancers and models, including in xenograft human lymphoma (Karpas), allograft murine colorectal carcinoma (CT26), and patient derived (PDX) Pancreatic (PDAC) and sarcoma mice models. Anti-CD3 fusions have a similar efficacy and safety profile in mouse models, with a dramatic effect on tumor growth and results in either complete stop of tumor growth or full tumor regression depending on the model.
Tumor burden and relative body weight evolution in mice cancer models for Lymphoma (Karpas 299) and murine colorectal carcinoma (CT26)
Phase 0: A First-in-Human Microdosing Study
Our first clinical study will start in Q3 2024, and for which we already achieved scale-up production milestones. This first trial will take the shape of nuclear imaging, first-in-human study with ~ 30 patients in a basket trial format. We expect this study to provide us with the pharmacokinetics and biodistribution of Vartumabs in patients with cancer, paving the way for efficacy trials.